China SXT Pharmaceuticals (SXTC) Competitors $1.59 -0.03 (-1.85%) Closing price 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SXTC vs. VIR, KALV, AMLX, AVBP, IMTX, IMNM, NUVB, MGTX, GYRE, and AUTLShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), ArriVent BioPharma (AVBP), Immatics (IMTX), Immunome (IMNM), Nuvation Bio (NUVB), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. Its Competitors Vir Biotechnology KalVista Pharmaceuticals Amylyx Pharmaceuticals ArriVent BioPharma Immatics Immunome Nuvation Bio MeiraGTx Gyre Therapeutics Autolus Therapeutics Vir Biotechnology (NASDAQ:VIR) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Is VIR or SXTC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -2,769.04%. China SXT Pharmaceuticals' return on equity of 0.00% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Vir Biotechnology-2,769.04% -47.46% -39.33% China SXT Pharmaceuticals N/A N/A N/A Does the media prefer VIR or SXTC? In the previous week, Vir Biotechnology had 4 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for Vir Biotechnology and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.87 beat Vir Biotechnology's score of 0.81 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Vir Biotechnology Positive China SXT Pharmaceuticals Very Positive Which has higher earnings & valuation, VIR or SXTC? China SXT Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVir Biotechnology$74.21M10.52-$521.96M-$4.22-1.34China SXT Pharmaceuticals$1.93M95.59-$3.10MN/AN/A Do analysts rate VIR or SXTC? Vir Biotechnology presently has a consensus price target of $30.25, suggesting a potential upside of 435.40%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, VIR or SXTC? Vir Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Do insiders and institutionals have more ownership in VIR or SXTC? 65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryVir Biotechnology beats China SXT Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.96M$2.50B$5.70B$9.51BDividend YieldN/A1.75%4.69%4.01%P/E RatioN/A9.0528.0720.05Price / Sales95.59757.64448.5799.42Price / CashN/A165.2136.2258.56Price / Book0.015.168.665.87Net Income-$3.10M$30.99M$3.25B$258.55M7 Day Performance-3.34%7.74%4.20%2.23%1 Month Performance-7.56%16.18%10.82%12.76%1 Year Performance-82.49%-1.03%34.70%19.36% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals1.2378 of 5 stars$1.59-1.9%N/A-82.2%$187.96M$1.93M0.0090Positive NewsGap UpVIRVir Biotechnology3.7018 of 5 stars$5.50-2.7%$30.25+450.0%-43.0%$760.32M$74.21M-1.30580KALVKalVista Pharmaceuticals4.1141 of 5 stars$15.22+4.8%$26.29+72.7%+7.8%$760.24MN/A-4.12100High Trading VolumeAMLXAmylyx Pharmaceuticals3.2987 of 5 stars$8.41+9.5%$11.75+39.7%+332.3%$749.68M-$1.27M-2.70200High Trading VolumeAVBPArriVent BioPharma2.1702 of 5 stars$21.87+1.1%$39.29+79.6%+4.6%$748.24MN/A-5.8040Positive NewsAnalyst ForecastAnalyst RevisionIMTXImmatics2.8128 of 5 stars$6.11+2.3%$14.67+140.0%-47.9%$742.67M$168.65M-35.94260News CoveragePositive NewsIMNMImmunome1.9176 of 5 stars$8.51-1.5%$23.33+174.2%-25.9%$740.46M$9.04M-2.6840Positive NewsNUVBNuvation Bio1.8672 of 5 stars$2.15-2.1%$7.17+232.7%-30.1%$732.92M$7.87M-0.9260MGTXMeiraGTx4.281 of 5 stars$8.89+5.0%$24.00+170.0%+82.2%$714.40M$33.28M-3.83300Insider TradeGYREGyre Therapeutics0.1574 of 5 stars$7.61+1.6%N/A-51.0%$713.51M$105.76M380.6940Positive NewsAUTLAutolus Therapeutics2.6058 of 5 stars$2.65+7.3%$9.32+251.7%-38.5%$705.27M$10.12M-3.01330 Related Companies and Tools Related Companies Vir Biotechnology Alternatives KalVista Pharmaceuticals Alternatives Amylyx Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Immatics Alternatives Immunome Alternatives Nuvation Bio Alternatives MeiraGTx Alternatives Gyre Therapeutics Alternatives Autolus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTC) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTC Stock Alerts